DIAZ REINALDO M 4

What Happened

• Reinaldo M. Diaz, a director of Lexeo Therapeutics, received a grant/award of derivative securities representing 35,000 shares on 2026-06-25. The reported acquisition price is $0.00, indicating an equity award or option rather than an open-market purchase; reported value at grant is $0.

Key Details

• Transaction date: 2026-06-25; Form 4 filed: 2026-06-29 (timely under the two-business-day rule).
• Instrument: Derivative award (code A on Form 4); reported acquisition price $0.00; total reported cash value $0.
• Vesting: Footnote F1 states 100% of the shares underlying the option vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, subject to continuous service.
• Shares owned after transaction: not specified in the provided filing summary.
• No 10b5-1 plan, tax-withholding, sale, or exercise was reported in this filing.

Context

• This is an equity award/option grant (no cash paid by the insider at grant). Such awards are compensation-related and do not represent an immediate purchase or sale of shares.
• Future value depends on any exercise price and company stock performance; vesting in up to one year means the award becomes exercisable relatively soon if the director remains in service.